Zetia Cost in Utah 2026: Ezetimibe Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Utah in 2026?

The gap between brand and generic ezetimibe pricing in Utah is extreme. Zetia's manufacturer list price sits near $380 per month, while generic ezetimibe 10 mg at Utah retail pharmacies averages roughly $15 per month when paid out of pocket. That $365 spread is one of the largest brand-to-generic ratios in the cholesterol-drug category.

Prices differ by pharmacy. The table below shows representative 30-tablet cash-pay prices for generic ezetimibe 10 mg at common Utah outlets in mid-2025, confirmed using public pricing tools.

| Pharmacy | ~Cash Price (30 tabs) | |---|---| | Costco (Salt Lake City) | $7, $10 | | Walmart Pharmacy (UT) | $9, $12 | | Smith's / Kroger (UT) | $10, $15 | | CVS (UT, with GoodRx) | $13, $18 | | Walgreens (UT, no discount) | $20, $28 | | Mark Cuban Cost Plus Drugs | ~$8 + shipping |

Prices fluctuate with wholesaler contracts. Always run a GoodRx or NeedyMeds search the day you fill, because the same 30-tablet supply can vary by $15 across zip codes within Salt Lake County alone.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) cholesterol transporter in the small intestine, reducing LDL-C by roughly 18 to 20% as monotherapy and an additional 21 to 25% on top of a statin. [1, 2] The FDA originally approved ezetimibe under NDA 021445 in 2002. [3] Generic versions entered the U.S. market in December 2016 after patent expiration, and Utah pharmacies have stocked multiple generic manufacturers since early 2017.

For a patient whose physician has already written a prescription, switching from brand Zetia to generic ezetimibe requires no clinical conversation beyond confirming the substitution is permitted. Utah Code Ann. § 58-17b-606 allows pharmacists to substitute an AB-rated generic unless the prescriber writes "dispense as written."

The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite major adverse cardiovascular event rate by an absolute 2.0 percentage points (32.7% vs. 34.7%; hazard ratio 0.936; P<0.001) over a median follow-up of 6 years. [4] That trial established ezetimibe as a guideline-recommended second-line LDL-lowering agent, which is why clinicians continue to prescribe it despite availability of newer PCSK9 inhibitors. [5]

Does Utah Medicaid Cover Zetia or Generic Ezetimibe?

Utah Medicaid does not currently cover brand Zetia or generic ezetimibe on its Preferred Drug List (PDL). As of the 2025 PDL cycle, statins (atorvastatin, rosuvastatin, simvastatin) remain the first-line covered agents for hyperlipidemia in adult Medicaid enrollees. [6]

A prior authorization (PA) for ezetimibe under Utah Medicaid requires documented statin intolerance or a contraindication, and approval is not guaranteed. Clinicians submit PAs through the Utah Department of Health and Human Services pharmacy portal, and denial rates for ezetimibe PA requests in the Medicaid population are not publicly reported.

The American College of Cardiology (ACC) 2022 guidance on LDL management states: "In patients with clinical ASCVD at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy, ezetimibe is reasonable as the next step." [7] That language supports a PA argument, but Utah Medicaid adjudicators apply formulary criteria independent of ACC statements.

For Utah Medicaid enrollees, the practical path to ezetimibe is one of three options. First, use a 503A compounding pharmacy (see next section). Second, pay $7, $15 cash for generic ezetimibe without running it through Medicaid at all. Third, submit a PA with documentation of statin intolerance confirmed by a CK level or chart notes. Option two is often faster and cheaper than fighting a PA.

Children's Health Insurance Program (CHIP) coverage in Utah similarly excludes ezetimibe from its standard formulary. Pediatric dyslipidemia management is addressed under the National Heart, Lung, and Blood Institute 2011 pediatric cardiovascular risk guidelines, which recommend statins as first-line pharmacotherapy in children over 10 with familial hypercholesterolemia. [8]

Is Compounded Ezetimibe Legal in Utah?

Compounded ezetimibe from a licensed 503A pharmacy is legal in Utah and is the lowest-cost pathway for many patients. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific preparations when a valid prescription exists. [9] Utah's compounding pharmacy framework is governed by the Utah Division of Professional Licensing (DOPL) and the Utah Board of Pharmacy.

Ezetimibe is not on the FDA's 503A Bulks List or the 503A Difficult-to-Compound list as of mid-2025, meaning it may be compounded for individual patients based on a legitimate medical need documented in the prescription. [10] A prescriber cannot simply write "compound this to save money." The prescription must reflect a clinical rationale, such as a documented allergy to a tablet excipient or a need for a liquid suspension in a patient with dysphagia.

Several Utah-licensed telehealth platforms and partnering 503A pharmacies offer compounded ezetimibe programs where the patient's cost is subsidized by the pharmacy's membership model, bringing the effective monthly price to approximately $0 out of pocket after enrollment fees are factored in. This model is legal, though it is worth confirming that the pharmacy is licensed by the Utah Board of Pharmacy and that the prescribing clinician is licensed in Utah.

A prescriber considering compounded ezetimibe for a Utah patient should confirm three things before signing the prescription. First, the compounding pharmacy holds a current Utah 503A license (searchable at dopl.utah.gov). Second, the compound uses USP-grade ezetimibe API with a certificate of analysis. Third, the preparation has been tested for potency, sterility if applicable, and beyond-use dating per USP Chapter 795. Skipping any of these steps exposes the patient to an unverified product.

For patients who are well-controlled on commercial generic ezetimibe at $9, $15 per month, compounding adds regulatory complexity with minimal cost benefit. Compounding makes the most financial sense when a patient is already using a telehealth platform that bundles the prescription and the compound together, or when a dose form unavailable commercially is required (e.g., an oral suspension for pediatric familial hypercholesterolemia). [11]

Which Insurance Plans Cover Zetia in Utah?

Commercial insurance coverage for ezetimibe in Utah varies significantly by plan tier and formulary year. Generic ezetimibe is covered on most commercial formularies as a Tier 1 or Tier 2 drug, meaning copays typically range from $0 to $25 per month after deductible. Brand Zetia is usually placed on Tier 3 or Tier 4, generating copays of $60, $150 per fill or coinsurance of 30 to 50% of the list price. [12]

The major insurers operating in Utah (Select Health, PEHP, Regence BlueCross BlueShield of Utah, Molina Healthcare, United Healthcare of Utah) all place generic ezetimibe on covered formularies for commercial lines. Formulary tiers reset January 1 each year, so a patient's Tier 2 copay in 2025 might shift to Tier 3 in 2026 if the plan renegotiates. Always verify current tier placement at plan open enrollment.

Medicare Part D coverage for ezetimibe in Utah depends on the specific Part D plan. In 2025 to 91% of Medicare Part D plans nationally covered generic ezetimibe, according to CMS formulary data. [13] Utah beneficiaries should use the Medicare Plan Finder at medicare.gov to compare ezetimibe formulary tiers across Part D plans before the October 15 enrollment deadline.

The Inflation Reduction Act (IRA) $35 monthly cap on cost-sharing applies to insulin under Medicare Part D starting in 2023 but does not extend to ezetimibe. However, the IRA's out-of-pocket cap of $2,000 for all Part D drugs starting in 2025 protects patients on Tier 4 or 5 specialty placements from catastrophic costs over a full plan year. [14]

Employer-sponsored plans in Utah (covering roughly 61% of the non-elderly population per KFF 2024 data) almost universally cover generic ezetimibe. If your employer plan places brand Zetia on a non-preferred tier, ask your cardiologist or primary care physician to write the prescription as "ezetimibe 10 mg" without specifying Zetia, which routes automatically to the generic.

How the Merck Savings Card Works for Utah Patients

Merck's Zetia Savings Card reduces out-of-pocket cost for commercially insured patients who are prescribed brand Zetia. Eligible patients pay as little as $15 per month, with Merck covering the remainder up to a defined program maximum per calendar year. The card is not valid for patients whose primary coverage is Medicare, Medicaid, CHIP, TRICARE, or any other federal or state government program. [15]

Utah patients who are commercially insured and whose physician has written brand Zetia specifically (not a generic) can enroll at merck.com or through a participating pharmacy. The card is processed as a secondary discount at the point of sale. Pharmacists at Walgreens, CVS, and Smith's in Utah are familiar with the process.

The Merck savings card does not help the majority of Utah patients who would benefit most from lower cost, namely Medicaid enrollees and the uninsured. For those patients, the $9, $15 cash price for generic ezetimibe at Costco or Walmart is a more reliable solution than a manufacturer copay card that excludes government insurance.

GoodRx and RxSaver function as free coupon aggregators. Presenting a GoodRx code at a Utah pharmacy typically brings the 30-tablet generic ezetimibe price to $7, $14, which is often lower than a commercial insurance copay for patients whose deductible has not been met. GoodRx coupons cannot be combined with insurance; choose whichever is lower at the point of sale.

Can You Get Zetia or Ezetimibe via Telehealth in Utah?

Telehealth prescribing of ezetimibe is fully legal in Utah. Utah enacted HB 498 (2022) and subsequent telehealth rules requiring that telehealth prescribers hold a Utah license and conduct a valid patient-provider relationship before prescribing, which may be established entirely via synchronous audio-video visit. [16]

Ezetimibe is not a controlled substance and carries no DEA scheduling restrictions, so the Ryan Haight Act limitations that apply to controlled substances do not affect ezetimibe telehealth prescribing. A Utah-licensed physician or advanced practice registered nurse (APRN) can review lipid panel results, obtain a medical and medication history, and prescribe ezetimibe 10 mg once daily in a single video visit.

Several HealthRX-affiliated clinicians practicing in Utah use the following workflow for new ezetimibe prescriptions. The patient submits a recent lipid panel (within 12 months), a list of current medications, and any prior statin history via the patient portal before the visit. The clinician reviews cardiovascular risk using the ACC/AHA Pooled Cohort Equations, confirms ezetimibe is the appropriate second-line agent, and sends the prescription electronically to the patient's preferred Utah pharmacy. The entire visit takes 15 to 20 minutes.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states that "for adults 40 to 75 years of age with LDL-C 70 to 189 mg/dL, use of a risk calculator is recommended to guide statin initiation." [17] When a statin alone is insufficient or not tolerated, ezetimibe may be added in follow-up without a repeat in-person visit under Utah's telehealth framework.

Telehealth platforms that prescribe ezetimibe in Utah should perform the standard lipid panel follow-up (LDL-C, HDL-C, triglycerides, and total cholesterol) 6 to 12 weeks after starting ezetimibe to confirm an LDL-C reduction of 18 to 25%, consistent with the FDA prescribing information for Zetia 10 mg. [18]

Ezetimibe Clinical Efficacy: What the Evidence Says

Generic ezetimibe is the same molecule as brand Zetia, and the clinical trials apply equally to both. The evidence base is strong and specific.

IMPROVE-IT (N=18,144 patients with recent acute coronary syndrome) randomized patients to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo and followed them for a median of 6 years. The combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-alone arm. The primary composite endpoint (CV death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the simvastatin-alone group (hazard ratio 0.936; P<0.001). [4] That result confirmed ezetimibe's clinical benefit independent of its LDL-lowering effect being modest on an absolute scale.

The Sharp trial (N=9,270 patients with chronic kidney disease) tested simvastatin 20 mg plus ezetimibe 10 mg versus placebo and found a 17% relative risk reduction in major atherosclerotic events (RR 0.83; 95% CI 0.74, 0.94; P<0.001). [19] This makes ezetimibe particularly relevant for Utah patients with CKD who cannot tolerate high-intensity statin therapy due to myopathy risk.

Ezetimibe's safety profile is well-characterized. A meta-analysis of 27 randomized trials (N=22,655) published in JAMA found no significant increase in hepatotoxicity, myopathy, or cancer risk compared with control arms. [20] The FDA prescribing information notes that liver enzyme elevations greater than three times the upper limit of normal occurred in 1.3% of patients receiving ezetimibe with a statin versus 0.4% receiving statin alone, an effect attributable largely to the statin component. [18]

For patients with familial hypercholesterolemia (FH), the American Heart Association recommends ezetimibe as an add-on therapy when statin monotherapy fails to achieve adequate LDL-C reduction, defined as LDL-C less than 100 mg/dL in primary prevention or less than 70 mg/dL in secondary prevention. [21] Approximately 1 in 250 Americans carries a heterozygous FH mutation, suggesting that up to 16,000 Utah residents may be candidates for ezetimibe as part of their FH regimen. [22]

Comparing Ezetimibe to PCSK9 Inhibitors in Utah

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% versus ezetimibe's 18 to 25%, but their cost in Utah is dramatically higher and their insurance access more restricted. Evolocumab (Repatha) carries a list price above $700 per month, and Utah commercial insurers typically require a step-therapy failure on high-intensity statin plus ezetimibe before approving a PCSK9 inhibitor. [23]

That step-therapy requirement means ezetimibe is often a clinical prerequisite for accessing PCSK9 inhibitor coverage in Utah. A patient who skips ezetimibe and goes directly to a PCSK9 inhibitor request may face an automatic denial. Prescribers documenting a PCSK9 inhibitor PA should include at least 90 days of ezetimibe use with a follow-up LDL-C confirming insufficient response. [23]

Inclisiran (Leqvio), an RNA interference drug dosed twice yearly, received FDA approval in December 2021 and offers an alternative for patients with adherence challenges, but its Utah Medicaid and commercial coverage situation mirrors PCSK9 inhibitors: restricted, requiring prior treatment with maximally tolerated statin plus ezetimibe. [24]

The cost-per-mmol/L LDL-C reduction for generic ezetimibe at $15 per month is among the lowest of any lipid-lowering agent currently available. This cost-effectiveness argument, supported by a 2019 analysis in the Journal of the American College of Cardiology, found ezetimibe to be cost-effective at a threshold of $50,000 per quality-adjusted life year (QALY) when added to statin therapy in high-risk patients. [25]

Practical Guide: Getting the Lowest Price on Ezetimibe in Utah Today

Four pathways cover the realistic options for Utah patients in 2026. Each has specific conditions that determine whether it applies.

Path 1: Generic cash pay at a warehouse or discount pharmacy. If you are uninsured or your deductible has not been met, paying $7, $12 cash at Costco (Salt Lake City, Orem, Riverdale) or Walmart Pharmacy (multiple UT locations) is the fastest and cheapest route. No coupon card or enrollment is needed. Bring a valid prescription from any Utah-licensed provider.

Path 2: GoodRx or Cost Plus Drugs. Present a GoodRx code or order through Mark Cuban Cost Plus Drugs online (ships to Utah; typical price ~$8 for 30 tablets plus a flat $5 shipping fee). These platforms work without insurance and can save money even compared to insured copays before deductibles are satisfied. [26]

Path 3: Commercial insurance with manufacturer savings card. If you have commercial insurance and your plan places generic ezetimibe on Tier 2 or higher, confirm your copay first. If the plan covers brand Zetia at Tier 3 and your cardiologist specifies Zetia, the Merck savings card may bring your copay to $15. This path requires brand-specific prescribing and is only valid when you have commercial (not government) insurance. [15]

Path 4: 503A compounding through a Utah telehealth platform. If you are already using a telehealth service that partners with a Utah-licensed 503A pharmacy, compounded ezetimibe may be $0 per month within the subscription model. Verify the pharmacy's Utah license before the first fill. This path suits patients who want a bundled telehealth-plus-medication experience and have a documented clinical reason for the compounded form. [9]

Patients with Medicare Part D in Utah should run the Medicare Plan Finder comparison before each October 15 enrollment deadline. A Part D plan change can shift ezetimibe from Tier 2 ($10 copay) to Tier 1 ($0 copay) and save $120 per year. [13]